Atrys Health, S.A. (BME:ATRY)
Spain · Delayed Price · Currency is EUR 2.810
-0.120 (-4.10%)
Sep 16, 2026, 5:35 PM CET
Atrys Health Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 147.68 | 141.01 | 129.98 | 201.57 | 158.37 | 121.01 |
Revenue Growth | 4.73% | 8.49% | -35.52% | 27.28% | 30.87% | 285.44% |
Gross Profit Gross Profit Growth | 24.58 | 21.62 | 25.45 | 52.61 | 42.11 | 31.35 |
Operating Income Operating Income Growth | -7.71 | -10.4 | -0.16 | -1.58 | -10.75 | -4.03 |
Net Income Net Income Growth | -97.39 | -100.3 | -31.77 | -45.59 | -23.15 | -23.26 |
Earnings Per Share EPS Growth | -1.28 | -1.32 | -0.42 | -0.60 | -0.34 | -0.46 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Medicine Precision - Diagnosis Medicine Precision - Diagnosis Growth | 68.84 | 71.39 | - | - |
Medicine Precision - Oncology Medicine Precision - Oncology Growth | 75.48 | 63.49 | 58.03 | 35.42 |
Total Total Growth | 144.31 | 134.88 | 206.1 | 163.2 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 12.84 | 13.58 | 20.88 | 42.38 | 36.06 | 35.23 |
Total Debt Total Debt Growth | 118.42 | 257.87 | 255.4 | 253.93 | 241.15 | 200.58 |
Net Cash (Debt) Net Cash Growth | -105.59 | -244.29 | -234.52 | -211.55 | -205.09 | -165.35 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.39 | -3.22 | -3.09 | -2.79 | -3.01 | -3.29 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -4.73 | -1.56 | 3 | 5.7 | -15.43 | 4.69 |
Capital Expenditures CapEx Growth | -3.97 | -6.49 | -4.25 | -6.25 | -6.77 | -4.22 |
Free Cash Flow Free Cash Flow Growth | -8.7 | -8.05 | -1.25 | -0.55 | -22.2 | 0.47 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 16.65% | 15.33% | 19.58% | 26.10% | 26.59% | 25.90% |
Operating Margin | -5.22% | -7.38% | -0.13% | -0.78% | -6.79% | -3.33% |
Pretax Margin | -33.30% | -39.86% | -26.64% | -16.72% | -16.92% | -20.56% |
Profit Margin | -65.95% | -71.13% | -24.45% | -22.62% | -14.62% | -19.22% |
FCF Margin | -5.89% | -5.71% | -0.96% | -0.27% | -14.02% | 0.39% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | 27.69 | 17.00 | 156.74 | 25.81 | 29.58 | 36.01 |
P/FCF Ratio | - | - | - | - | - | 1318.37 |
PS Ratio | 1.51 | 1.58 | 1.97 | 1.38 | 2.88 | 5.13 |